Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC study
Year: 2021
Type: article
Abstract: Colorectal cancer is the second leading cause of cancer deaths worldwide, with a 5-year relative survival of 14% in patients with metastatic colorectal cancer (mCRC). Patients with BRAF V600E mutations, which occur in ∼10%-15% of patients with mCRC, have a poorer prognosis compared with those with wild-type BRAF tumours. The combination of the BRAF inhibitor encorafenib with the epidermal growth factor receptor inhibitor cetuximab currently represents the only chemotherapy-free targeted therapy approved in the USA and Europe for previously treated patients with BRAF V600E-mutated mCRC. As a class, BRAF inhibitors are associated with dermatologic, gastrointestinal, and renal events, as well as pyrexia and secondary skin malignancies. Adverse event (AE) profiles of specific BRAF inhibitors vary, however, and are affected by the specific agents given in combination. In patients with mCRC, commonly reported AEs of cetuximab monotherapy include infusion reactions and dermatologic toxicities. Data from the phase III BEACON CRC study indicate that the combination of encorafenib with cetuximab has a distinct safety profile. Here we review the most frequently reported AEs that occurred with this combination in BEACON CRC and best practices for managing and mitigating AEs that require more than standard supportive care.
Source: ESMO Open
Institutions: Vall d'Hebron Institute of Oncology, The University of Texas MD Anderson Cancer Center, West Cancer Center, Memorial Sloan Kettering Cancer Center, Universitair Ziekenhuis Leuven, KU Leuven, Hammersmith Hospital, The Royal Melbourne Hospital, Peter MacCallum Cancer Centre, National Cancer Center Hospital East, Pfizer (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,140
Funders: Amgen, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, Bayer, GlaxoSmithKline, Merck, Novartis, Roche, Sanofi, Celgene, Memorial Sloan-Kettering Cancer Center, Array BioPharma, Boehringer Ingelheim, Merck KGaA, Les Laboratories Pierre Fabre, Daiichi-Sankyo, Shire, MedImmune, Servier, Ono Pharmaceutical, Ipsen, Sirtex Medical, Genentech, Merck Sharp and Dohme, Chugai Pharmaceutical, Fondation Pierre Fabre, National Cancer Institute
Award: Cancer Center Support Grant
OpenAlex ID: W4200582980